112 related articles for article (PubMed ID: 32267009)
1. Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
Colado A; Marín Franco JL; Elías EE; Amondarain M; Vergara Rubio M; Sarapura Martínez V; Cordini G; Fuentes F; Balboa L; Fernandez Grecco H; Pavlovsky M; Bezares F; Morande P; Giordano M; Gamberale R; Borge M
Am J Hematol; 2020 Jul; 95(7):E174-E178. PubMed ID: 32267009
[No Abstract] [Full Text] [Related]
2. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
Front Immunol; 2020; 11():2158. PubMed ID: 32983178
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib blocks Btk-dependent NF-ĸB and NFAT responses in human macrophages during
Bercusson A; Colley T; Shah A; Warris A; Armstrong-James D
Blood; 2018 Nov; 132(18):1985-1988. PubMed ID: 30021784
[No Abstract] [Full Text] [Related]
4. BTK/PD-1 blockade for treatment of Richter's transformation.
Tang PS; Tam CS
Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820
[No Abstract] [Full Text] [Related]
5. CLL in focus: news in the treatment of chronic lymphocytic leukemia.
Schuyler D
Clin Adv Hematol Oncol; 2020 Oct; 18(10):627-628. PubMed ID: 33201868
[No Abstract] [Full Text] [Related]
6. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
8. BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-α.
Vargas-Blanco DA; Hepworth OW; Basham KJ; Simaku P; Crossen AJ; Timmer KD; Hopke A; Brown Harding H; Vandal SR; Jensen KN; Floyd DJ; Reedy JL; Reardon C; Mansour MK; Ward RA; Irimia D; Abramson JS; Vyas JM
JCI Insight; 2024 May; 9(12):. PubMed ID: 38713531
[TBL] [Abstract][Full Text] [Related]
9. BTK Inhibitors and Chemoimmunotherapy for CLL.
Thompson P
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S22-S24. PubMed ID: 32862855
[No Abstract] [Full Text] [Related]
10. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
Taneja A; Jones J; Pittaluga S; Maric I; Farooqui M; Ahn IE; Wiestner A; Sun C
Leuk Lymphoma; 2019 Feb; 60(2):519-522. PubMed ID: 29978754
[No Abstract] [Full Text] [Related]
11. Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Alkharabsheh O; Alsayed A; Morlote DM; Mehta A
Curr Oncol; 2021 Feb; 28(1):837-841. PubMed ID: 33567487
[TBL] [Abstract][Full Text] [Related]
12. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
13. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
Zent CS; Brady MT; Delage C; Strawderman M; Laniewski N; Contant PN; Kanagaiah P; Sangster MY; Barr PM; Chu CC; Topham DJ; Friedberg JW
Leukemia; 2021 Jun; 35(6):1788-1791. PubMed ID: 33128020
[No Abstract] [Full Text] [Related]
14. Next-Generation Bruton Tyrosine Kinase Inhibitors.
Stephens DM; Byrd JC
J Clin Oncol; 2020 Sep; 38(25):2937-2940. PubMed ID: 32673168
[No Abstract] [Full Text] [Related]
15. Intestinal colonization by Candida albicans alters inflammatory responses in Bruton's tyrosine kinase-deficient mice.
Strijbis K; Yilmaz OH; Dougan SK; Esteban A; Gröne A; Kumamoto CA; Ploegh HL
PLoS One; 2014; 9(11):e112472. PubMed ID: 25379804
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma.
Liu J; Liang Q; Wang A; Zou F; Qi Z; Yu K; Liu Q; Chen C; Liu J; Liu Q
Signal Transduct Target Ther; 2020 Sep; 5(1):200. PubMed ID: 32929063
[No Abstract] [Full Text] [Related]
17. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
[TBL] [Abstract][Full Text] [Related]
18. Environmental dimensionality controls the interaction of phagocytes with the pathogenic fungi Aspergillus fumigatus and Candida albicans.
Behnsen J; Narang P; Hasenberg M; Gunzer F; Bilitewski U; Klippel N; Rohde M; Brock M; Brakhage AA; Gunzer M
PLoS Pathog; 2007 Feb; 3(2):e13. PubMed ID: 17274685
[TBL] [Abstract][Full Text] [Related]
19. How neutrophils kill fungi.
Gazendam RP; van de Geer A; Roos D; van den Berg TK; Kuijpers TW
Immunol Rev; 2016 Sep; 273(1):299-311. PubMed ID: 27558342
[TBL] [Abstract][Full Text] [Related]
20. Second-Generation Bruton's Tyrosine Kinase Inhibitors: Simply the Best Treatments for Chronic Lymphocytic Leukemia?
Stephens DM
J Clin Oncol; 2021 Nov; 39(31):3419-3422. PubMed ID: 34310198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
